Walleye Capital’s Coya Therapeutics COYA Stock Holding History

Walleye Capital’s Portfolio COYA Stock Details COYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37,062	Closed	-$215K	–	4483
2025 Q4	$215K	Buy	+37,062	New	+$225K	﹤0.01%	3506

Other funds holding COYA

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

PMG

Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Walleye Capital's COYA Position: Q1 2026 in Review

Walleye Capital sold out of Coya Therapeutics (COYA) in Q1 2026, closing a stake of 37,062 shares — an estimated $215K sold.

Walleye Capital first reported a position in COYA in Q4 2025 and held it in 1 quarter. The position peaked at $215K in Q4 2025. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

Walleye Capital reported no remaining Coya Therapeutics position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 37,062 Coya Therapeutics shares in Q1 2026, an estimated $215K.
Walleye Capital first reported a position in Coya Therapeutics in Q4 2025 and held it in 1 quarter.
Walleye Capital's Coya Therapeutics position peaked at $215K in Q4 2025.
56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.